Pharvaris Company Description

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.

The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris N.V.

Country	Netherlands
Founded	2015
Industry	Biological Products, Except Diagnostic Substances
Employees	108
CEO	Berndt Axel Modig

Contact Details

Address: Grafenauweg 8 Zug, 6300 Switzerland
Phone	31 712036410
Website	pharvaris.com

Stock Details

Ticker Symbol	9EN
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Berndt Axel Modig	Chief Executive Officer
David Nassif	Chief Financial Officer